Literature DB >> 35821070

Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol).

Elodie Fiot1, Bertille Alauze1, Bruno Donadille2, Dinane Samara-Boustani3, Muriel Houang4, Gianpaolo De Filippo1, Anne Bachelot5, Clemence Delcour6, Constance Beyler7, Emilie Bois8, Emmanuelle Bourrat9, Emmanuel Bui Quoc10, Nathalie Bourcigaux2, Catherine Chaussain11, Ariel Cohen12, Martine Cohen-Solal13, Sabrina Da Costa14, Claire Dossier15, Stephane Ederhy12, Monique Elmaleh16, Laurence Iserin17, Hélène Lengliné18, Armelle Poujol-Robert19, Dominique Roulot20, Jerome Viala18, Frederique Albarel21, Elise Bismuth22, Valérie Bernard23, Claire Bouvattier24, Aude Brac25, Patricia Bretones25, Nathalie Chabbert-Buffet26, Philippe Chanson27, Regis Coutant28, Marguerite de Warren29, Béatrice Demaret30, Lise Duranteau31, Florence Eustache32, Lydie Gautheret1, Georges Gelwane1, Claire Gourbesville33, Mickaël Grynberg34, Karinne Gueniche14, Carina Jorgensen35, Veronique Kerlan36, Charlotte Lebrun1, Christine Lefevre37, Françoise Lorenzini38, Sylvie Manouvrier39, Catherine Pienkowski40, Rachel Reynaud41, Yves Reznik33, Jean-Pierre Siffroi42, Anne-Claude Tabet43, Maithé Tauber44, Vanessa Vautier45, Igor Tauveron46, Sebastien Wambre47, Delphine Zenaty1, Irène Netchine4, Michel Polak3, Philippe Touraine5, Jean-Claude Carel1, Sophie Christin-Maitre2, Juliane Léger48.   

Abstract

Turner syndrome (TS; ORPHA 881) is a rare condition in which all or part of one X chromosome is absent from some or all cells. It affects approximately one in every 1/2500 liveborn girls. The most frequently observed karyotypes are 45,X (40-50%) and the 45,X/46,XX mosaic karyotype (15-25%). Karyotypes with an X isochromosome (45,X/46,isoXq or 45,X/46,isoXp), a Y chromosome, X ring chromosome or deletions of the X chromosome are less frequent. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins) is to provide health professionals with information about the optimal management and care for patients, based on a critical literature review and multidisciplinary expert consensus. The PNDS, written by members of the French National Reference Center for Rare Growth and Developmental Endocrine disorders, is available from the French Health Authority website. Turner Syndrome is associated with several phenotypic conditions and a higher risk of comorbidity. The most frequently reported features are growth retardation with short adult stature and gonadal dysgenesis. TS may be associated with various congenital (heart and kidney) or acquired diseases (autoimmune thyroid disease, celiac disease, hearing loss, overweight/obesity, glucose intolerance/type 2 diabetes, dyslipidemia, cardiovascular complications and liver dysfunction). Most of the clinical traits of TS are due to the haploinsufficiency of various genes on the X chromosome, particularly those in the pseudoautosomal regions (PAR 1 and PAR 2), which normally escape the physiological process of X inactivation, although other regions may also be implicated. The management of patients with TS requires collaboration between several healthcare providers. The attending physician, in collaboration with the national care network, will ensure that the patient receives optimal care through regular follow-up and screening. The various elements of this PNDS are designed to provide such support.
© 2022. The Author(s).

Entities:  

Keywords:  Adulthood; Childhood; Diagnosis; Management; Recommendation; Turner’s syndrome

Mesh:

Year:  2022        PMID: 35821070      PMCID: PMC9277788          DOI: 10.1186/s13023-022-02423-5

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.303


  115 in total

1.  The Turner syndrome life course project: Karyotype-phenotype analyses across the lifespan.

Authors:  Antoinette Cameron-Pimblett; Clementina La Rosa; Thomas F J King; Melanie C Davies; Gerard S Conway
Journal:  Clin Endocrinol (Oxf)       Date:  2017-07-24       Impact factor: 3.478

2.  Cardiovascular outcomes of pregnancy in Turner syndrome.

Authors:  Jasmine Grewal; Anne Marie Valente; Alexander C Egbe; Fred M Wu; Eric V Krieger; Virginia P Sybert; Iris M van Hagen; Luc M Beauchesne; Fred H Rodriguez; Craig S Broberg; Anitha John; Elisa A Bradley; Jolien W Roos-Hesselink
Journal:  Heart       Date:  2020-07-15       Impact factor: 5.994

Review 3.  Turner syndrome and pregnancy: clinical practice. Recommendations for the management of patients with Turner syndrome before and during pregnancy.

Authors:  Laure Cabanes; Celine Chalas; Sophie Christin-Maitre; Brun Donadille; Marie Louise Felten; Valerie Gaxotte; Guillaume Jondeau; Emmanuel Lansac; Jacques Lansac; Hélène Letur; Tatia N'Diaye; Jeanine Ohl; Anne Pariente-Khayat; Dominique Roulot; François Thepot; Delphine Zénaty
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-07-01       Impact factor: 2.435

Review 4.  Clinical update on sensorineural hearing loss in Turner syndrome and the X-chromosome.

Authors:  Åsa Bonnard; Rusana Bark; Christina Hederstierna
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-01-10       Impact factor: 3.908

5.  Long-term safety of recombinant human growth hormone in children.

Authors:  J Bell; K L Parker; R D Swinford; A R Hoffman; T Maneatis; B Lippe
Journal:  J Clin Endocrinol Metab       Date:  2009-11-11       Impact factor: 5.958

6.  Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency.

Authors:  Jacob P Christ; Marlise N Gunning; Giulia Palla; Marinus J C Eijkemans; Cornelis B Lambalk; Joop S E Laven; Bart C J M Fauser
Journal:  Fertil Steril       Date:  2018-03-28       Impact factor: 7.329

7.  Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial.

Authors:  Emma Jane Gault; Tim J Cole; Sarah Casey; Peter C Hindmarsh; Peter Betts; David B Dunger; Malcolm D C Donaldson
Journal:  Arch Dis Child       Date:  2019-12-20       Impact factor: 3.791

8.  Metabolic Syndrome as a Risk Factor for Sensorineural Hearing Loss in Adult Patients with Turner Syndrome.

Authors:  Francisco Álvarez-Nava; Marcia Racines-Orbe; Julia Witt; Jéssica Guarderas; Yosselin Vicuña; María Estévez; Roberto Lanes
Journal:  Appl Clin Genet       Date:  2020-01-13

9.  The Natural History of Metabolic Comorbidities in Turner Syndrome from Childhood to Early Adulthood: Comparison between 45,X Monosomy and Other Karyotypes.

Authors:  Yael Lebenthal; Sigal Levy; Efrat Sofrin-Drucker; Nessia Nagelberg; Naomi Weintrob; Shlomit Shalitin; Liat de Vries; Ariel Tenenbaum; Moshe Phillip; Liora Lazar
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-09       Impact factor: 5.555

10.  No QTc Prolongation in Girls and Women with Turner Syndrome.

Authors:  Iris D Noordman; Anthonie L Duijnhouwer; Misty Coert; Melanie Bos; Marlies Kempers; Henri J L M Timmers; Zina Fejzic; Janiëlle A E M van der Velden; Livia Kapusta
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.